Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe

Provides Important Foundation as Company Advances European Commercial Plans for ARIKACE to Treat Lung Infections in Cystic Fibrosis Patients

Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the European Patent Office intends to grant E.U. Patent No. 1909759 for ARIKACE® (liposomal amikacin for inhalation). Once granted, the composition of matter patent provides exclusivity in any of the European Patent Office's member states where Insmed chooses to file at least through July 19, 2026. The Company's liposomal amikacin for inhalation is in clinical development to treat cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections and patients with nontuberculous mycobacteria (NTM) lung infections.

Published: 15 May 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Insmed Incorporated ( INSM )

Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in China

-Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9-

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is responsible for the current influenza outbreak in China.

Published: 08 May 2013
Written by Editor
TSX   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Medicago Inc ( MDG )

Santarus Reports First Quarter 2013 Financial Results

Total revenues increase 73% with significant increase in net income over prior year period

Raises 2013 financial outlook to include total revenues of $330 million to $340 million, net income of $57 million to $64 million and non-GAAP adjusted earnings of $81 million to $91 million

Santarus, Inc. (SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2013.

Key financial results for the 2013 first quarter include:

Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013. The poster will be presented today, April 29th, by Dr. Miriam Kidron, Oramed's Chief Scientific Officer, between 5:00pm-7:00pm EDT during the poster session and evening reception in the Ballroom Foyer of the Hyatt Regency Hotel.

Published: 29 April 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Oramed Pharmaceuticals Inc ( ORMP )

OPKO Health To Acquire PROLOR Biotech

—Acquisition Adds Promising Late Stage Product hGH-CTP Targeting Growth Hormone Deficiency and Preclinical Products Targeting Hemophilia, Obesity & Diabetes—
—Complementary Drug Development Technologies Strengthen OPKO's Innovation Leadership—
—PROLOR to Host Conference Call at 8:30 A.M. EDT Thursday, April 25 to Discuss Transaction—

OPKO Health, Inc. (OPK) and PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the companies have signed a definitive merger agreement under which OPKO will acquire PROLOR, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins, in an all-stock transaction. 

Published: 24 April 2013
Written by Editor
AMEX   Healthcare   M & A   Up on News   Interesting News  
Read more: PROLOR Biotech Inc ( PBTH )
  1. Medgenics Inc ( MDGN )
  2. Neuralstem Inc ( CUR )
  3. ARCA biopharma Inc ( ABIO )
  4. Vertex Pharmaceuticals Incorporated ( VRTX )
  5. Neuralstem Inc ( CUR )